FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2558 December 9, 2004 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lubinski, S. M. PubMed Citation

To the Editor: Lubinski and Hendrix (Aug. 19 issue)¹ provide interesting images of a VIPoma. They report hypercalcemia (serum calcium level, 12.1 mg per deciliter [3.0 mmol per liter]) in the patient but do not provide any information regarding the cause. Rarely, hypercalcemia in this setting could indicate the presence of multiple endocrine neoplasia type 1² and, consequently, the need for genetic screening. Cosecretion of calcitonin by the neuroendocrine tumor of the pancreas is another possibility.³

Biswa M. Mishra, M.D.
Christie Hospital
Manchester M20 4BX, United Kingdom
biswa.mishra@christie-tr.nwest.nhs.uk

1. Lubinski SM, Hendrix T. VIPoma. N Engl J Med 2004;351:808-808. [Free Full Text]
2. Cesani F, Ernst R, Walser E, Villanueva-Meyer J. Tc-99m sestamibi imaging of a pancreatic VIPoma and parathyroid adenoma in a patient with multiple type I endocrine neoplasia. Clin Nucl Med 1994;19:532-534. [Medline]
3. Ichimura T, Kondo S, Okushiba S, Morikawa T, Katoh H. A calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome. Int J Gastrointest Cancer 2003;33:99-102. [Medline]